On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research preparation with FDA-identified safety uncertainty.
What the evidence shows
Parent-peptide evidence is contested
Experiments with unmodified or stabilized MGF peptides failed to reproduce claimed stimulation of human and mouse muscle cells. These findings limit confidence in broad parent-peptide claims. [1]
Modification requires separate evidence
The negative MGF study is not a clinical trial of PEG-MGF. It also cannot answer whether a specific pegylated product behaves differently in people. [1]
What remains unknown
Reliable human pharmacokinetics, recovery outcomes, and interaction data for the exact PEG-MGF preparation are not established by the cited sources.
Safety
FDA assessment
FDA flags immune-response and impurity concerns and reports no identified human exposure data for PEG-MGF products. [2]
The precise modified molecule matters
FDA identifies PEG-MGF separately from other peptides. Its identity and impurity concerns cannot be resolved by borrowing a parent peptide’s handling instructions. [2]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does “long-acting” prove that it lasts a known number of days?
No. A design intention requires pharmacokinetic measurements for the exact formulation before a human duration can be claimed.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells2014 · Primary research · PubMed
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · Compound-specific safety assessment
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.